Final Evidence Report and Meeting Summary

PDF cover

Diabetes: Final Report

This report examines the comparative effectiveness and value of insulin degludec (Tresiba®), Novo Nordisk A/S) for the treatment of diabetes mellitus. It includes a systematic review of the published evidence, as well as an economic analysis that examines cost-effectiveness and budget impact of the drug. The results of these analyses are used to produce an ICER value-based price benchmark; a price that reflects the magnitude of estimated improvements in long-term patient outcomes and thresholds for new drug costs that do not exceed growth in the overall national economy.


View All Materials on this Topic or Go Back to View More Materials